Genmab — December 2014
-
I morgen får vi så dara+revlimid kl. 21-22.30 og så Dara multikombostudiet engang midt om natten DK time
-
Tweets som den her giver en god indikator på hvor vi
-
...skal hen Jacob Plieth @JacobEPVantage 9m9 minutes ago
Bullish doc comments re anti-CD38s in MM: potential blockbusters that should move to front line $SNY $GEN.CO $MOR $JNJ $CELG #ASH14 -
Arzerra CLL præsentationen er lagt op nu: http://files.shareholder.com/downloads/AMDA-KPIBN/3395652340x0x798268/071E6540-55F2-4445-9590-DC97472A2E4C/ASH_PROLONG_FINAL.pdf
-
Der er ikke noget vildt i den. PFS data det mest ophidsende og dem har vi fået fø
-
spændende hvad FDA siger. om de mener det er pengene værd
-
-
Although median overall survival was not reached in either group in this interim analysis, there was a trend toward longer overall survival in the group who received carfilzomib (73.3% vs 65%; HR = 0.79; P=.018). However, the results did not cross the prespecified statistical boundary set by the statisticians when the trial s
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind